BeyondSpring Inc. — FY2023 Form 20-F
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 filing; quarterly results are not separately provided in the supplied text. Financial statements are prepared under U.S. GAAP and amounts below are in U.S. dollars.
Business context
BeyondSpring is a clinical-stage biopharmaceutical company with no approved products and no product-sales revenue. Its lead candidate, Plinabulin, is being developed for cancer indications and chemotherapy-induced neutropenia (CIN). Its subsidiary SEED is developing a targeted protein degradation platform and collaborates with Eli Lilly.
Financial performance and position
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1.751 million | $1.351 million |
| Research and development | $14.635 million | $25.582 million |
| General and administrative | $10.230 million | $13.008 million |
| Operating loss | $23.114 million | $37.239 million |
| Net loss | $21.948 million | $36.280 million |
| Net loss attributable to BeyondSpring | $21.026 million | $33.279 million |
| Net loss per share, basic and diluted | $0.54 | $0.85 |
| Cash used in operating activities | $16.474 million | $28.151 million |
- Revenue increased 30%, principally from Lilly collaboration and milestone activity; no revenue came from product sales. Plinabulin accounted for no segment revenue.
- R&D expense fell 43% and G&A fell 21%, primarily due to lower clinical, NDA-support, personnel and professional-services costs. The lower net loss therefore reflects reduced spending, not product commercialization.
- At year-end, cash and cash equivalents were $7.809 million, restricted cash was $9.941 million, and short-term investments were $0.193 million. Combined, these totaled $17.943 million, down from $37.268 million at year-end 2022.
- Current assets were $18.419 million and current liabilities $7.958 million, implying working capital of $10.461 million. Total liabilities were $48.269 million; $34.993 million was deferred revenue, principally the unrecognized Hengrui upfront payment, and $3.995 million was operating lease liabilities. The 2019 bank loan was repaid in 2022; the filing reports no interest expense for 2023.
- Shareholders’ deficit was $35.335 million, and accumulated deficit was $396.302 million. Contingently redeemable SEED noncontrolling interests of $11.874 million are presented as mezzanine equity.
Material changes, outlook and risks
- Operating cash use declined from $28.2 million to $16.5 million, but cash, cash equivalents and restricted cash decreased by $16.6 million in 2023. The company reported no net proceeds from equity sales during the year.
- Management expects continuing losses and negative cash flows and says additional financing is required. The auditor’s report includes a going-concern explanatory paragraph, stating that substantial doubt exists about the company’s ability to continue as a going concern. There is no assurance that financing will be available on acceptable terms; equity financing could dilute shareholders.
- For CIN, the FDA issued a Complete Response Letter in November 2021, stating the pivotal PROTECTIVE-2 results were not sufficiently robust and that another well-controlled trial would be required. BeyondSpring withdrew its China CIN NDA in March 2023 and says it is discussing a possible refiling with the NMPA.
- For NSCLC, management reports positive DUBLIN-3 Phase 3 topline results, including median overall survival of 10.5 months versus 9.4 months and a hazard ratio of 0.82. The trial included approximately 87% patients in China; the FDA may require additional evidence, and no marketing approval is reported. Management plans to pursue an NMPA filing.
- Hengrui sought termination of its Greater China collaboration and repayment of its upfront fee. An arbitration award on January 10, 2024 denied Hengrui’s claims; the approximately $9.6 million of frozen assets was returned in February 2024. The $31.0 million upfront payment remains deferred revenue, not recognized product revenue.
- SEED may receive up to approximately $780 million in potential Lilly milestones plus royalties, but these are contingent and not assured. The filing reports $1.751 million revenue in 2023 from the Lilly collaboration.
- Other notable controls risk: management identified two material weaknesses in financial reporting controls, and concluded disclosure controls were ineffective at December 31, 2023. The weaknesses involved review of reconciliations/consolidations and journal entries, resulting in material post-closing adjustments.
Most important facts for investors to verify
- Available, unrestricted cash and the company’s financing runway, given that $9.941 million of reported cash was restricted at year-end and going-concern doubt was disclosed.
- The regulatory path and funding needs for another FDA CIN trial, any NMPA refiling, and an NSCLC application, including whether regulators accept the existing clinical data.
- Progress on remediating the two material weaknesses and whether future filings report effective controls.
- Terms, timing and likelihood of Hengrui milestone or royalty receipts and of Lilly’s contingent milestones; distinguish deferred or potential amounts from recognized revenue and cash received.
- SEED’s preferred-share redemption terms, including the 8% annual return and redemption rights exercisable from November 10, 2025, and the potential effect on liquidity and ownership.